Stock comparison
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BRKRP
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
Market cap
$53.05B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BRKRP | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 38D | 70B | HAE |
| Benjamin Graham | 45D | 85A | HAE |
| Philip Fisher |
Side-by-side metrics
| Metric | BRKRP | HAE |
|---|---|---|
| Market cap | $53.05B | $2.98B |
| P/E (TTM) | - | 24.8x |
| EV/EBIT | 59.6x | 14.1x |
| ROIC (TTM) | -2.92% | 8.37% |
| Gross margin | 45.56% | 55.74% |
| Net margin | -0.34% | 7.29% |
| Revenue CAGR 5y | 9.19% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BRKRP leads on
- P/E (TTM)-vs 24.8x+104%
- Dividend yield0.45%vs 0.0%+100%
- Market cap$53.05Bvs $2.98B+94%
- Debt / Equity0.7xvs 1.5x
More like HAE
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.